Results 181 to 190 of about 69,132 (251)

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, Volume 32, Issue 30, 13 August 2026.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source

Prediction of Patients' Response to Immune Checkpoint Inhibitors Using Fluorescence Lifetime Imaging of Lymphocytes. [PDF]

Biomedicines
Yuzhakova DV, Kononova AI, Izosimova AV, Sazhina MM, Dudenkova VV, Elagin VV, Bureev PA, Kuzmin DA, Gavrina AI, Shumskaya IS, Gamaynov SV, Shirmanova MV.   +11 more
europepmc   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu, Ji Eun Ryoo, Brian S. Henick, Adam Mor   +3 more
wiley   +1 more source

Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review. [PDF]

Breast Cancer (Dove Med Press)
Abbaspour M, Esmaeil N, Akbari V, Ghoreishi M, Rafiepoor H.   +4 more
europepmc   +1 more source

Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma

Advanced Science, Volume 13, Issue 44, 7 August 2026.
This review explains how chronic liver injury progresses toward hepatocellular carcinoma through interconnected changes in gut microbes, metabolism, immunity, fibrosis, and diet. It highlights microbial metabolites, bile‐acid signaling, immune dysfunction, and nutritional or microbiome‐based interventions as opportunities to identify risk earlier ...
Yi Hu, Caiyan Lin, Lijie Zhang, Xue Jiang, Huawen Li, Yangzhe Wu   +5 more
wiley   +1 more source

Ipilimumab, -omics, and head and neck cancers-update in 2025. [PDF]

Front Immunol
Kucharski R, Kosiński A, Kalinowski L, Kaźmierczak-Siedlecka K.   +3 more
europepmc   +1 more source

Microbiota–Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma

Brain and Behavior, Volume 16, Issue 8, August 2026.
Microbiota–neuroinflammation crosstalk in GBM. The schematic summarizes how gut microbiota and microbiota‐derived signals may influence GBM biology through gut–brain signaling, microbial metabolites, systemic immune modulation, BBB‐related pathways, tumor‐associated microbial signals, and immune‐metabolic changes within the GBM microenvironment.
Tareq Nayef AlRamadneh, Renuka Jyothi S, Priya Priyadarshini Nayak, Anima Nanda, Shaker Al Hasnaawei, Akanksha Bhatt, Ashish Singh Chauhan, Siya Singla, Mehrdad Nourizadeh   +8 more
wiley   +1 more source

Evaluation of +49 A>G (rs231775) Variant in CTLA4 Gene and SCTLA-4 Serum Levels in Plaque Psoriasis in a Mestizo Mexican Population. [PDF]

Int J Mol Sci
Cortés-Ruiz MG, Wheber-Hidalgo KA, Hernández-Nicols BF, Buenrostro-Camacho FG, Hernández-Bello J, Graciano-Machuca O, Alvarado-Navarro A.   +6 more
europepmc   +1 more source

Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma.
Shen Li, Alexandra E. Rojek, Reid Shaw, Cristina O’Donoghue, J. Michael Millis, Daniel J. Olson   +5 more
wiley   +1 more source

Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3. [PDF]

Sci Rep
Shousha SA, Ibrahim SSA, Kadry H, Youssef EA, Qabany Y, Darwish AA, Metwea A, Baheeg SA, Shahine Y.   +8 more
europepmc   +1 more source